Post Profile






Synairgen says AstraZeneca stops mid-stage asthma drug study

(Reuters) - Drug developer Synairgen Plc said its partner AstraZeneca Plc stopped a mid-stage study that was testing Synairgen's drug candidate as a potential treatment for severe asthma.
read more

share

Related Posts


Clinical studies published in The Lancet Respiratory Medicine highlight RPL554 as a promising novel potential treatment for asthma and COPD

Health : Medical News Today

Verona Pharma plc (AIM: VRP), the drug development company focused on "first-in-class" medicines to treat respiratory diseases, announces that a new research paper entitled "Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibi...

AstraZeneca seeks edge over rivals in severe asthma treatment

Health : Reuters: Health

LONDON (Reuters) - AstraZeneca hopes to convince doctors its experimental injection for severe asthma has an edge over two approved rivals after clinical trials data on Monday showed it worked well when given just once every two mon...

AstraZeneca starts final-stage tests on severe asthma drug

News : The Newsroom

AstraZeneca said on Thursday it was starting final-stage Phase III clinical trials for its experimental drug tralokinumab as a treatment for severe asthma. The drug, which showed promising results in mid-stage trials in May, was amo...

FDA places Regeneron and Teva's pain-drug study on hold

Health : Reuters: Health

(Reuters) - Regeneron Pharmaceuticals Inc and partner Teva Pharmaceutical Industries Ltd said the U.S. health regulator placed a clinical hold on a study testing their pain treatment, dealing another blow to companies looking to dev...

Glaxo, AstraZeneca Shares Fall After FDA Finds Asthma Drug Risk - BusinessWeek

Medical / Pharmaceutical : PharmaGossip

via businessweek.com GlaxoSmithKline Plc and AstraZeneca Plc declined in London trading after U.S. regulators warned against long-term use of their Advair and Symbicort asthma drugs and called for further study of their potential he...

Comments


Copyright © 2016 Regator, LLC